Goldman Sachs Initiates Coverage of Genomic Health with Neutral Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs today initiated coverage of Genomic Health with a Neutral rating and a six-month price target on its stock of $36.

In a research note, analyst Isaac Ro noted the growth potential of the Redwood City, Calif.-based firm's new products, but said that costs associated with those products will offset growth. Additionally, the company faces increased competition as well as a murky regulatory environment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.